Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal C-tetanus toxoid conjugate vaccine
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **meningococcal C-tetanus toxoid conjugate vaccine** is a monovalent vaccine designed to protect against invasive disease caused by *Neisseria meningitidis* serogroup C. The vaccine contains purified capsular polysaccharide from serogroup C meningococci conjugated to tetanus toxoid (TT) protein. Conjugation to tetanus toxoid facilitates a T-cell dependent immune response, promoting higher and longer-lasting antibody titers, increased immunogenicity in infants and young children, and immunological memory. Primary indication is the prevention of invasive meningococcal disease (including meningococcal meningitis and septicemia) caused by serogroup C. The vaccine is administered intramuscularly; its mechanism of action is induction of anti-serogroup C polysaccharide-specific antibodies via targeted immunological engagement with the conjugated tetanus toxoid protein carrier[2][3].
- Brand names
- Nimenrix
- Other names
- MenC-TTNimenrixmeningococcal conjugate vaccine serogroup C-tetanus toxoidMenC vaccine (TT)
02
Targets
TT (Tetanus toxoid)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal C-tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal C-tetanus toxoid conjugate vaccine.